China Resources Double-Crane Pharmaceutical Co Ltd Cash Flow Quality Index
China Resources Double-Crane Pharmaceutical Co Ltd cash flow quality index. China Resources Double-Crane Pharmaceutical Co Ltd (600062) has a Cash Flow Quality Index of 1.30x as of September 2025. Operating cash flow of CN¥487.90 Million exceeds net income of CN¥374.04 Million, indicating high earnings quality where cash backs reported profits. Explore 600062 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of China Resources Double-Crane Pharmaceutical Co Ltd (1998–2024)
Cash flow quality index of China Resources Double-Crane Pharmaceutical Co Ltd from 1998 to 2024. Historical Cash Flow Quality Index for China Resources Double-Crane Pharmaceutical Co Ltd across 26 annual periods. Values consistently above 1.0x indicate high-quality earnings. See net asset quality index of China Resources Double-Crane Pharmaceuti to measure how much of total assets are equity-financed.
China Resources Double-Crane Pharmaceutical Co Ltd Cash Flow Quality Index by Year (1998–2024)
China Resources Double-Crane Pharmaceutical Co Ltd cash flow quality index by year from 1998 to 2024. Year-by-year earnings quality comparison for China Resources Double-Crane Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see 600062 cash flow conversion.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.11x | CN¥1.83 Billion | CN¥1.65 Billion | ▼ -11.2% |
| 2023 | 1.25x | CN¥1.65 Billion | CN¥1.33 Billion | ▲ +12.8% |
| 2022 | 1.10x | CN¥1.34 Billion | CN¥1.22 Billion | ▼ -20.0% |
| 2021 | 1.38x | CN¥1.34 Billion | CN¥972.13 Million | ▲ +2.8% |
| 2020 | 1.34x | CN¥1.36 Billion | CN¥1.01 Billion | ▼ -0.6% |
| 2019 | 1.35x | CN¥1.44 Billion | CN¥1.07 Billion | ▼ -9.1% |
| 2018 | 1.48x | CN¥1.47 Billion | CN¥989.45 Million | ▲ +10.3% |
| 2017 | 1.35x | CN¥1.19 Billion | CN¥882.10 Million | ▲ +29.0% |
| 2016 | 1.04x | CN¥771.25 Million | CN¥739.25 Million | ▼ -1.1% |
| 2015 | 1.05x | CN¥701.35 Million | CN¥664.82 Million | ▼ -20.2% |
| 2014 | 1.32x | CN¥718.38 Million | CN¥543.66 Million | ▲ +111.3% |
| 2013 | 0.63x | CN¥546.24 Million | CN¥873.44 Million | ▼ -0.4% |
| 2012 | 0.63x | CN¥396.05 Million | CN¥630.55 Million | ▼ -32.2% |
| 2011 | 0.93x | CN¥511.53 Million | CN¥552.52 Million | ▼ -3.2% |
| 2010 | 0.96x | CN¥509.67 Million | CN¥533.00 Million | ▲ +29.6% |
| 2009 | 0.74x | CN¥342.01 Million | CN¥463.45 Million | ▼ -11.8% |
| 2008 | 0.84x | CN¥331.71 Million | CN¥396.46 Million | ▲ +62.6% |
| 2007 | 0.51x | CN¥235.46 Million | CN¥457.61 Million | ▼ -69.6% |
| 2006 | 1.69x | CN¥303.71 Million | CN¥179.22 Million | ▲ +130.3% |
| 2005 | 0.74x | CN¥139.78 Million | CN¥189.97 Million | ▼ -74.5% |
| 2003 | 2.89x | CN¥148.94 Million | CN¥51.55 Million | ▲ +200.2% |
| 2002 | 0.96x | CN¥140.63 Million | CN¥146.15 Million | ▲ +10.6% |
| 2001 | 0.87x | CN¥141.01 Million | CN¥162.05 Million | ▼ -30.2% |
| 2000 | 1.25x | CN¥172.81 Million | CN¥138.60 Million | ▼ -28.7% |
| 1999 | 1.75x | CN¥131.54 Million | CN¥75.25 Million | ▲ +875.2% |
| 1998 | -0.23x | CN¥-13.78 Million | CN¥61.13 Million | — |